Computer-aided designing of oncolytic viruses for overcoming translational challenges of cancer immunotherapy. Issue 7 (July 2020)

• Record Type: Journal Article
• Authors: Lathwal, Anjali; Kumar, Rajesh; Raghava, Gajendra P.S.
• Is Part Of: Drug discovery today. Volume 25:Issue 7(2020)
• Page Start: 1198
• Page End: 1205
• Publication Date: 2020-07
• Subjects: Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2020.04.008
• Languages: English
• ISSNs: 1359-6446

Abstract

Highlights: The role of oncolytic viruses in cancer therapy has been discussed. Some popular current strategies to improve oncolytic virotherapy are discussed. We comment on current critical issues associated with oncolytic virotherapy. Computer-aided viral therapy may play a crucial role in oncolytic virotherapy. Optimally designed oncolytic viruses may provide better therapeutic options. Abstract : Wild-type and genetically engineered oncolytic viruses (OVs) represent powerful therapeutic agents in cancer immunotherapy. Several OV species are in clinical trials for cancer treatment. Preclinical and clinical trials revealed several issues related to OV therapy in terms of viral delivery, spread, antiviral immune response, and tumor resistance. Here, we suggest some promising computational strategies that can overcome these issues. The strategies include predicting and prioritizing tumor-homing peptides, anticancer peptides, neoantigens, and miRNA response elements in the viral genome. The combination of computational approaches with genetic engineering could enhance the safety, delivery, oncolysis, and antitumor immune responses of OVs.